The Enterprise DG of the European Commission retained Charles River Associates to undertake a study investigating whether there is a worldwide crisis in innovation in the pharmaceutical sector, the reasons behind this crisis, and the tools available to kick-start innovation.
Keytruda and PD(L)1: Life after programmed death (part 2)
Looking ahead, we see a proliferation of PD-(L)1’s role; particularly in uses that go beyond traditional monoclonal, single-target antibodies (mAbs). Not only...